Biologics Extremities Top Stories Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion byWill SandbergDecember 2, 2025
Biologics Spine Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 byWill SandbergOctober 3, 2025
Biologics Spine Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance byJosh SandbergAugust 5, 2025
Biologics Extremities Spine Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich byTim AllenMay 13, 2025
Financial Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 byTim AllenApril 15, 2025
Biologics Spine Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division byJosh SandbergJanuary 7, 2025
Biologics Extremities Top Stories Kuros Biosciences Expands into Extremities Markets byTim AllenNovember 19, 2024
Biologics Extremities Top Stories Foot Innovate Welcomes New Corporate Partner: Kuros Biosciences byTim AllenOctober 9, 2024
Financial Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023 byJosh SandbergMarch 13, 2024
Biologics Regulatory Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand byJosh SandbergJanuary 31, 2024
